Daina Graybosch
Stock Analyst at Leerink Partners
(0)
# 4616
Out of 5,243 analysts
131
Total ratings
31.82%
Success rate
-17.42%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Merck & Co | Maintains: Outperform | 136 119 | 100.13 | 18.85% | 19 | Jan 13, 2025 | |
LAVA Therapeutics | Downgrades: Market Perform | 11 2 | 0.97 | 106.19% | 6 | Dec 12, 2024 | |
Bolt Biotherapeutics | Downgrades: Market Perform | 3 1 | 0.52 | 92.31% | 8 | May 15, 2024 | |
2seventy bio | Upgrades: Outperform | 5 18 | 2.43 | 640.74% | 5 | Jan 31, 2024 | |
Arcellx | Maintains: Outperform | 35 39 | 64.78 | -39.8% | 5 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 5 3 | 0.92 | 226.09% | 10 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 20 14 | 0.91 | 1438.46% | 4 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 62 10 | 1.34 | 646.27% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 100 60 | 1.08 | 5455.56% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 10 9 | 1.61 | 459.01% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 40 38 | 14.24 | 166.85% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 30 8 | 5.66 | 41.34% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 223 224 | 114.81 | 95.1% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 30 | 2.23 | 1245.29% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 21 7 | n/a | n/a | 4 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 60 59 | 7.74 | 662.27% | 7 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 18 17 | 1.39 | 1123.02% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 25 2 | n/a | n/a | 6 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 16 9 | 2 | 350% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 5 6 | n/a | n/a | 2 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 68 | n/a | n/a | 1 | Dec 11, 2019 |